PubMed Health⌕ Search

PubMed · 12651500

Temporal variability in basal isoprene emission factor.

Abstract

Seasonal variability in basal isoprene emission factor (&mgr;g C g(-1) h(-1) or nmol m(-2) s(-1), leaf temperature at 30 degrees C and photosynthetically active radiation (PAR) at 1000 &mgr;mol m(-2) s(-1)) was studied during the 1998 growing season at Duke Forest in the North Carolina Piedmont. Emissions from eight upper-canopy white oak (Quercus alba L.) leaves were measured periodically from the onset of isoprene emission on Day of Year (DOY) 119 (April 29) to leaf senescence in late October (DOY 299). Emissions from four leaves were measured under basal conditions with a controlled-environment cuvette system equipped with 10-ml gas-tight syringes and a reduction gas detector. Emissions from the other four leaves were measured under ambient conditions with the same system. Emission rates from the four leaves measured under ambient conditions were adjusted to basal conditions based on the PAR and leaf temperature algorithms of Guenther et al. (1993). The seasonal onset of isoprene emission was in agreement with previous studies where cumulative degree days from the date of the last spring frost were used to estimate bud break, leaf expansion, and increase in basal emission factor (EF). Between DOY 141 (May 21) and 240 (August 28), mean meteorological conditions 6 to 18 h prior to the EF measurements (ambient PAR and temperature) explained up to 78% of the variability in mean basal EF between measurement periods. Summertime mean isoprene emission potential was reached on DOY 141 (May 21) and was maintained until DOY 240 (August 28), when isoprene emission began to decline monotonically as leaf senescence approached. The mean value for leaves measured under ambient conditions and adjusted to basal conditions for DOY 141-240 was 75.6 &mgr;g C g(-1) h(-1) (74.2-79.1), whereas the mean value for leaves measured under basal conditions was 72.9 &mgr;g C g(-1) h(-1) (64.7-88.9). Between DOY 141 and 240, daily mean isoprene EFs varied from 54 to 96 &mgr;g C g(-1) h(-1) (27 to 49 nmol m(-2) s(-1)). In agreement with previous work at this and other sites, basal isoprene emission rates of fully exposed leaves at the crown apex of this tree were about 20% higher than those of the selected leaves. The length of the period prior to measurement of isoprene emission, during which meteorology was correlated with basal EF, appeared to be related to the timing and periodicity of meteorological change, and probably explains quantitative differences in the length of this period among studies. The empirical equation that we derived for this effect explained variability in midday EFs at the study site, but its general applicability remains to be tested. Strong diurnal changes in EF (as high as a factor of 2) are implied in this study, and should be examined further.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Chris Geron, Alex Guenther, Tom Sharkey, Robert R. Arnts. 2000. Temporal variability in basal isoprene emission factor.. https://doi.org/10.1093/treephys%2F20.12.799

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗